329 related articles for article (PubMed ID: 26194447)
1. Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.
Vaughn JE; Gooley T; Maziarz RT; Pulsipher MA; Bhatia S; Maloney DG; Sandmaier BM; Flowers ME; Storb R; Sorror ML
Br J Haematol; 2015 Nov; 171(3):411-6. PubMed ID: 26194447
[TBL] [Abstract][Full Text] [Related]
2. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.
Sorror ML; Martin PJ; Storb RF; Bhatia S; Maziarz RT; Pulsipher MA; Maris MB; Davis C; Deeg HJ; Lee SJ; Maloney DG; Sandmaier BM; Appelbaum FR; Gooley TA
Blood; 2014 Jul; 124(2):287-95. PubMed ID: 24797298
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM; Penza S; Elder P; Cortright K; Kitzler R; Coombes K; O'Donnell L; Daneault B; Bradbury H; Zhang J; Chen X; Garman S; Ranganathan P; Yu X; Hofstetter J; Yu J; Garzon R; Scrape SR; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Jan; 22(1):71-9. PubMed ID: 26256940
[TBL] [Abstract][Full Text] [Related]
5. Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients.
Campregher PV; Hamerschlak N; Colturato VA; Mauad MA; de Souza MP; Bouzas LF; Tavares Rde C; Barros JC; Chiattone R; Paz A; Silla L; Vigorito AC; Miranda E; Funke VA; Flowers ME
Eur J Haematol; 2015 Nov; 95(5):421-5. PubMed ID: 25645430
[TBL] [Abstract][Full Text] [Related]
6. Relationship of body mass index and arm anthropometry to outcomes after pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies.
Hoffmeister PA; Storer BE; Macris PC; Carpenter PA; Baker KS
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1081-6. PubMed ID: 23623893
[TBL] [Abstract][Full Text] [Related]
7. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation.
ElSawy M; Storer BE; Pulsipher MA; Maziarz RT; Bhatia S; Maris MB; Syrjala KL; Martin PJ; Maloney DG; Sandmaier BM; Storb R; Sorror ML
Br J Haematol; 2015 Aug; 170(4):574-83. PubMed ID: 25945807
[TBL] [Abstract][Full Text] [Related]
8. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
[TBL] [Abstract][Full Text] [Related]
10. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation.
Mielcarek M; Burroughs L; Leisenring W; Diaconescu R; Martin PJ; Sandmaier BM; Maloney DG; Maris MB; Chauncey TR; Shizuru JA; Blume KG; Hegenbart U; Niederwieser D; Forman S; Bruno B; Woolfrey A; Storb R
Br J Haematol; 2005 May; 129(3):381-91. PubMed ID: 15842663
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
14. GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation.
Sakellari I; Barbouti A; Bamichas G; Mallouri D; Kaloyannidis P; Fragidis S; Batsis I; Apostolou C; Karpouza A; Yannaki E; Smias C; Sombolos K; Anagnostopoulos A
Bone Marrow Transplant; 2013 Oct; 48(10):1329-34. PubMed ID: 23584436
[TBL] [Abstract][Full Text] [Related]
15. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
16. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
[TBL] [Abstract][Full Text] [Related]
18. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.
Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi RJ; Hematti P; Kamble RT; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1327-1334. PubMed ID: 28461213
[TBL] [Abstract][Full Text] [Related]
19. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country.
Teixeira GM; Bittencourt H; de Macedo AV; Martinho GH; Colosimo EA; Rezende SM
PLoS One; 2015; 10(9):e0137390. PubMed ID: 26394228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
